Co-administration and Evaluation of Immune Responses of Three DNA Vaccines Encoding Immunogenic Antigens from Mycobacterium tuberculosis
2019
Background: Ineffectiveness of BCG vaccine in controlling tuberculosis (TB) and co-infection of TB and HIV have turned TB into a serious global threat. Therefore, the development of an alternative vaccine to BCG and/or antimycobacterial drugs is an urgent need. Here, three chimeric DNA constructs consisting of Mtb32C-HBHA, Ag85a-Tb10.4, and Ag85a-cfp10 made in our previous studies were co-administered to BALB/c mice to evaluate their immune responses using a prime-boost regimen in which the animals were first immunized with BCG and then administered with DNA vaccines. Methods: In order to evaluate the immunogenicity of three DNA constructs, the levels of several immunomodulatory cytokines were measured in vaccinated mice. Thirty female BALB/c mice were divided into the following groups (n = 10): control (receiving pcDNA 3.1+ intramuscularly), vaccine (receiving recombinant vectors intramuscularly), and vaccine-BCG (receiving BCG subcutaneously followed by recombinant vectors intramuscularly). Results: The levels of IL-4, IL-12, TGF-β, IFN-γ, and IL-10 were higher in the immunized groups than in the control group (P 0.05). Conclusions: Our results proved that using a chimeric DNA vaccine as a booster in the prime-boost strategy could significantly enhance the efficacy of BCG. This study suggests that the use of such DNA vaccines encoding mycobacterial immunogenic antigens as boosters enhances the efficacy of BCG.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
0
Citations
NaN
KQI